Home › Glaucoma › NCT06882356
The Glaucoma and Retinopathy Screening Study
The Glaucoma and Retinopathy Screening Study (GRaSS)
Who can join
Ages 40 and older · All sexes
Full eligibility criteria
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.
About the study
The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma.
Participants will:
Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset
What is being tested
- AI-based glaucoma screening (device)
- IOP measurement (device)
- Virtual Reality Visual Field Testing (device)
Sponsor: Massachusetts Eye and Ear Infirmary · Participants: 2,000 · Started: Jul 16, 2025
Contact the study team
- David S Friedman, MD, PhD, MPH · Phone: 617-573-3094
Official record on ClinicalTrials.gov — NCT06882356
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.